Market Overview:
The global chlamydia infection treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of chlamydia infections, rising awareness about available treatments, and growing demand for oral and injectable drugs. Based on type, the global chlamydia infection treatment market can be segmented into oral drugs, injectable drugs, and others. Oral drugs are expected to account for the largest share of this market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period. Injectable drugs are also expected to witness significant growth during the forecast period owing to their high efficacy and safety profile. Based on application, the global chlamydia infection treatment market can be divided into hospital pharmacy, online pharmacy, retail pharmacy, and others segments. The hospital pharmacy segment is anticipated to account for a major share of this market in 2018 owing its large customer base across hospitals worldwide.
Product Definition:
Chlamydia infection is a sexually transmitted disease caused by the bacterium Chlamydia trachomatis. It is the most common sexually transmitted disease in the United States. Symptoms include vaginal discharge, pain with urination, and bleeding after intercourse. Treatment includes antibiotics such as azithromycin or doxycycline. Chlamydia can be prevented by using condoms and other barrier methods during sex.
Oral:
Oral is a widely used treatment for chlamydia infections. It is the first line of treatment as it does not require any additional medication and can be started within 48 hours of infection. The main factor driving the growth factor in this market includes increasing prevalence rate of chlamydia infections, especially among young people, lack or unavailability of effective alternatives and favorable reimbursement scenario in developed countries like U.S.
Injectable:
Injectable is a medication that is administered by injection into the muscle, vein, or under the skin. It may also be given through a nasal spray. The drug works by reducing and eliminating the bacteria causing chlamydia infection in women (vaginitis) and men (chancroid).
The global injectable market size was valued at USD 21 billion in 2016 and it is expected to grow at a CAGR of XX% over the forecast period.
Application Insights:
Based on application, the global market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others. The hospital pharmacies held the largest share in 2017 owing to presence of key players such as Shoppers Drug Mart Corporation and Pfizer Inc. Hospital pharmacies offer complete range of services for management of chronic diseases such as diabetes and hypertension which attract a large number of patients requiring long-term medication.
The online pharmacies are expected to grow at fastest rate during forecast period due to increasing internet usage rates especially in developing regions like Asia Pacific and Latin America where internet penetration is still low but it is anticipated that this trend will change soon enough with time. Moreover, growing awareness about managing chronic diseases through eHealth platform will boost growth further driving it towards lucrative markets like China, India & Brazil by 2020 which eventually leads to highest revenue share for market players globally.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017, owing to the presence of a large number of market players and high awareness levels coupled with relatively higher healthcare expenditure in this region as compared to other regions. The Centers for Disease Control and Prevention (CDC) reported nearly 699,000 new cases of chlamydia infection in the U.S., as well as 35 million infections that went untreated in 2016.
Asia Pacific is expected to be one of the fastest growing regions during forecast years due to increasing prevalence rates, rising demand for cost-effective treatment options among patients along with rapid economic development witnessed by countries such as India and China over past few years which are anticipated to boost market growth during forecast period from 2018 to 2030 (ref). In addition, increasing investments by manufacturers such as Gilead Sciences Inc.; Merck & Co., Inc.; and Johnson & Johnson Ltd; are anticipated strengthen regional growth prospects over next seven years (ref).
Growth Factors:
- Increasing incidence of chlamydia infection: The incidence of chlamydia infection is increasing at a rapid pace across the globe. This is primarily attributed to changing sexual behavior and lack of awareness about the disease. This is expected to drive the demand for chlamydia infection treatment products in the coming years.
- Growing demand for point-of-care tests: The growing demand for point-of-care tests is another major growth driver for the global chlamydia infection treatment market. These tests are easy to use and provide results within minutes, which makes them ideal for use in clinics and hospitals.
- Rising prevalence of sexually transmitted infections: The rising prevalence of sexually transmitted infections (STIs) is another key factor that is expected to fuel the growth of the global chlamydia infection treatment market in the near future. Chlamydia, being one among several STIs, has been identified as a major public health concern across different regions worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chlamydia Infection Treatment Market Research Report
By Type
Oral, Injectable, Others
By Application
Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others
By Companies
Merck & Co. Inc. (US), Pfizer Inc (US), GlaxoSmithKline Plc(UK), AstraZeneca (UK), Gilead Sciences Inc. (US), Sanofi(France), TevaPharmaceuticals (Israel), Sun Pharma(India), Eli Lilly and Company (US), Novartis (Switzerland)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Chlamydia Infection Treatment Market Report Segments:
The global Chlamydia Infection Treatment market is segmented on the basis of:
Types
Oral, Injectable, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co. Inc. (US)
- Pfizer Inc (US)
- GlaxoSmithKline Plc(UK)
- AstraZeneca (UK)
- Gilead Sciences Inc. (US)
- Sanofi(France)
- TevaPharmaceuticals (Israel)
- Sun Pharma(India)
- Eli Lilly and Company (US)
- Novartis (Switzerland)
Highlights of The Chlamydia Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injectable
- Others
- By Application:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chlamydia Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chlamydia infection treatment typically includes antibiotics to clear the infection and often a prescription for contraception to prevent future infections.
Some of the key players operating in the chlamydia infection treatment market are Merck & Co. Inc. (US), Pfizer Inc (US), GlaxoSmithKline Plc(UK), AstraZeneca (UK), Gilead Sciences Inc. (US), Sanofi(France), TevaPharmaceuticals (Israel), Sun Pharma(India), Eli Lilly and Company (US), Novartis (Switzerland).
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chlamydia Infection Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chlamydia Infection Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chlamydia Infection Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chlamydia Infection Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chlamydia Infection Treatment Market Size & Forecast, 2020-2028
4.5.1 Chlamydia Infection Treatment Market Size and Y-o-Y Growth
4.5.2 Chlamydia Infection Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injectable
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Online Pharmacy
6.2.3 Retail Pharmacy
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chlamydia Infection Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chlamydia Infection Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injectable
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Online Pharmacy
9.10.3 Retail Pharmacy
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injectable
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Online Pharmacy
10.10.3 Retail Pharmacy
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injectable
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Online Pharmacy
11.10.3 Retail Pharmacy
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injectable
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Online Pharmacy
12.10.3 Retail Pharmacy
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injectable
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Online Pharmacy
13.10.3 Retail Pharmacy
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chlamydia Infection Treatment Market: Competitive Dashboard
14.2 Global Chlamydia Infection Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co. Inc. (US)
14.3.2 Pfizer Inc (US)
14.3.3 GlaxoSmithKline Plc(UK)
14.3.4 AstraZeneca (UK)
14.3.5 Gilead Sciences Inc. (US)
14.3.6 Sanofi(France)
14.3.7 TevaPharmaceuticals (Israel)
14.3.8 Sun Pharma(India)
14.3.9 Eli Lilly and Company (US)
14.3.10 Novartis (Switzerland)
